Skip to content

Michal Lotem

Hadassah Medical Center

2 papers in the Anchorcite directory, published between 2011 and 2015, cited 10,634 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations

    BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…

  2. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine · 2011 · 4,600 citations

    BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study…

Metadata from OpenAlex (CC0).